Nemolizumab 30 mg

BIOLOGICAL3 trials

Sponsors

Galderma R&D, University of Texas Southwestern Medical Center

Conditions

Atopic DermatitisLichen Sclerosus of VulvaPrurigo Nodularis

Phase 2

Nemolizumab for LS

Not yet recruitingNCT07704775

University of Texas Southwestern Medical CenterLichen Sclerosus of Vulva

Start: 2026-09-01End: 2027-12-01Target: 25Updated: 2026-07-15

Phase 3

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

CompletedNCT04501666

Galderma R&DPrurigo Nodularis

Start: 2020-09-11End: 2023-02-21Updated: 2024-07-10

Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis

Not yet recruitingNCT07762833

Galderma R&DAtopic Dermatitis

Start: 2026-09-28End: 2028-09-28Target: 240Updated: 2026-08-13

Related Papers

Cutaneous Safety Profile of Nemolizumab in Moderate‑to‑Severe Atopic Dermatitis and Prurigo Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&amp;2 and OLYMPIA 1&amp;2) Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&amp;2 and OLYMPIA 1&amp;2)

SKIN The Journal of Cutaneous Medicine2026-03-10

British Society for Skin Care in Immunosuppressed IndividualsOral presentationsBI01 Persistent nonpruritic scabies in a patient on nemolizumab for the treatment of prurigo nodularis

British Journal of Dermatology2025-06-27

Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.

2025-04-23

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

JAMA Dermatology2024-11-2732 citations

672 - Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies

British Journal of Dermatology2024-08-011 citations

673 - Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials

British Journal of Dermatology2024-08-01